Kathrin R.
- Country
- Germany
- Department
- 6113: Klinik fuer Neurologie
Research Overview
- Oral semaglutide versus placebo in early Alzheimer’s disease: a randomized double-blind trial in patients with mild cognitive impairment or mild dementia
- Randomized, Double‑Blind, Placebo‑Controlled Phase 3 Trial of Oral Votoplam in Adults with Huntington’s Disease Assessing cUHDRS Progression
- Evaluation of Safety and Efficacy of PRI-002 in Patients with Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 117 of 251 partner sites.
Specializations
Neurodegenerative Disorders
The investigator specializes in treating and researching neurodegenerative conditions, with particular emphasis on Huntington's Disease and Alzheimer's Disease.
- Prodromal and Early Manifest Huntington's Disease
- Early-stage Alzheimer's Disease
- Mild Cognitive Impairment (MCI)
Their expertise extends to evaluating novel therapeutic approaches for managing cognitive decline and neurological symptoms.
Clinical Assessment
The investigator employs advanced clinical assessment tools to monitor disease progression and treatment efficacy in neurological disorders.
- Unified Huntington's Disease Rating Scale
- Clinical Dementia Rating Scale
- Total Functional Capacity Assessment
Their work includes comprehensive evaluation of cognitive function and disease biomarkers.
Therapeutic Innovation
The investigator focuses on evaluating novel therapeutic agents targeting specific neurological pathways.
- Protein-targeting Therapeutics
- Biomarker Analysis
- Safety and Efficacy Assessment
Their research includes monitoring cerebrospinal fluid markers and advanced neuroimaging techniques.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.